Four weeks of treatment with the highest tested dose of the experimental therapy DT-216P2 was associated with improvements in functional scores for four people with Friedreich’s ataxia (FA) in an early clinical trial. Data also indicate that DT-216P2 was generally well tolerated and showed biomarker activity consistent with increasing…
